ES2377470T3 - Azitromicina para el tratamiento del acné nodular - Google Patents
Azitromicina para el tratamiento del acné nodular Download PDFInfo
- Publication number
- ES2377470T3 ES2377470T3 ES07838730T ES07838730T ES2377470T3 ES 2377470 T3 ES2377470 T3 ES 2377470T3 ES 07838730 T ES07838730 T ES 07838730T ES 07838730 T ES07838730 T ES 07838730T ES 2377470 T3 ES2377470 T3 ES 2377470T3
- Authority
- ES
- Spain
- Prior art keywords
- azithromycin
- acne
- treatment
- composition
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 156
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 148
- 238000011282 treatment Methods 0.000 title claims abstract description 104
- 229960004099 azithromycin Drugs 0.000 title claims abstract description 98
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims abstract description 98
- 230000002757 inflammatory effect Effects 0.000 claims description 39
- 238000002560 therapeutic procedure Methods 0.000 claims description 31
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 24
- 229960005280 isotretinoin Drugs 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 230000000699 topical effect Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 230000003255 anti-acne Effects 0.000 claims description 5
- 238000007910 systemic administration Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000002483 medication Methods 0.000 claims description 2
- 229940126703 systemic medication Drugs 0.000 claims 2
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 206010054107 Nodule Diseases 0.000 description 74
- 230000003902 lesion Effects 0.000 description 46
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 25
- 229960004023 minocycline Drugs 0.000 description 25
- 208000031513 cyst Diseases 0.000 description 16
- FZKWRPSUNUOXKJ-CVHRZJFOSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrate Chemical compound O.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O FZKWRPSUNUOXKJ-CVHRZJFOSA-N 0.000 description 13
- 229960003722 doxycycline Drugs 0.000 description 13
- 239000003242 anti bacterial agent Substances 0.000 description 11
- 206010033733 Papule Diseases 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000001815 facial effect Effects 0.000 description 10
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 9
- 206010037888 Rash pustular Diseases 0.000 description 9
- 239000004098 Tetracycline Substances 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 9
- 208000029561 pustule Diseases 0.000 description 9
- 235000019364 tetracycline Nutrition 0.000 description 9
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 8
- 229960002180 tetracycline Drugs 0.000 description 8
- 229930101283 tetracycline Natural products 0.000 description 8
- 150000003522 tetracyclines Chemical class 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 6
- 206010000503 Acne cystic Diseases 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229960003276 erythromycin Drugs 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- WTJXVDPDEQKTCV-VQAITOIOSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O WTJXVDPDEQKTCV-VQAITOIOSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 150000004683 dihydrates Chemical group 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 229940102079 solodyn Drugs 0.000 description 3
- 229940072172 tetracycline antibiotic Drugs 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960002916 adapalene Drugs 0.000 description 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 230000002995 comedolytic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000004682 monohydrates Chemical group 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229960000565 tazarotene Drugs 0.000 description 2
- -1 tetracycline compounds Chemical class 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 1
- 206010000513 Acne pustular Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010063655 Erosive oesophagitis Diseases 0.000 description 1
- 229930006677 Erythromycin A Natural products 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 206010050551 Lupus-like syndrome Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229960002421 minocycline hydrochloride Drugs 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 230000036619 pore blockages Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000037370 skin discoloration Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84906506P | 2006-10-03 | 2006-10-03 | |
| US849065P | 2006-10-03 | ||
| US11/635,127 US7704959B2 (en) | 2006-10-03 | 2006-12-06 | Azithromycin for the treatment of nodular acne |
| US635127 | 2006-12-06 | ||
| PCT/US2007/020583 WO2008042139A2 (en) | 2006-10-03 | 2007-09-24 | Azithromycin for the treatment of nodular acne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2377470T3 true ES2377470T3 (es) | 2012-03-27 |
Family
ID=39261797
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07838730T Active ES2377470T3 (es) | 2006-10-03 | 2007-09-24 | Azitromicina para el tratamiento del acné nodular |
| ES11188960.6T Active ES2574677T3 (es) | 2006-10-03 | 2007-09-24 | Azitromicina para el tratamiento del acné nodular |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11188960.6T Active ES2574677T3 (es) | 2006-10-03 | 2007-09-24 | Azitromicina para el tratamiento del acné nodular |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7704959B2 (enExample) |
| EP (2) | EP2086552B1 (enExample) |
| JP (1) | JP2010505827A (enExample) |
| KR (1) | KR20090064592A (enExample) |
| CN (2) | CN102614210A (enExample) |
| AT (1) | ATE533496T1 (enExample) |
| AU (1) | AU2007302663B2 (enExample) |
| BR (1) | BRPI0719535A2 (enExample) |
| CA (1) | CA2664673A1 (enExample) |
| CY (1) | CY1112650T1 (enExample) |
| DK (1) | DK2086552T3 (enExample) |
| ES (2) | ES2377470T3 (enExample) |
| MX (1) | MX2009003484A (enExample) |
| PL (2) | PL2420240T3 (enExample) |
| PT (1) | PT2086552E (enExample) |
| RU (1) | RU2009116629A (enExample) |
| SI (1) | SI2086552T1 (enExample) |
| WO (1) | WO2008042139A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124123B2 (en) * | 2007-09-05 | 2012-02-28 | Dow Pharmaceutical Sciences, Inc. | Controlled release azithromycin solid dosages forms |
| US8143227B2 (en) * | 2007-09-05 | 2012-03-27 | Dow Pharmaceutical Sciences, Inc. | Azithromycin for treatment of skin disorders |
| CN107281155B (zh) * | 2017-06-06 | 2020-04-10 | 扬子江药业集团四川海蓉药业有限公司 | 一种阿奇霉素片及其制备方法 |
| JP2020527607A (ja) * | 2017-07-21 | 2020-09-10 | アルミラール・リミテッド・ライアビリティ・カンパニーＡｌｍｉｒａｌｌ， Ｌｌｃ | 非炎症性病変の処置 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU43006B (en) | 1981-03-06 | 1989-02-28 | Pliva Pharm & Chem Works | Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof |
| US4474758A (en) | 1981-11-19 | 1984-10-02 | American Cyanamid Company | Haemophilus influenzae type b and pertussis outer membrane component combined vaccine |
| US4474768A (en) | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| US4474766A (en) | 1983-06-27 | 1984-10-02 | Merck & Co., Inc. | Anti-inflammatory/analgesic combination of cyclo-(N-methyl-Ala-Tyr-D-Trp-Lys-Val-Phe) and a selected non-steroidal anti-inflammatory drug (NSAID) |
| MX12213A (es) | 1987-07-09 | 1993-05-01 | Pfizer | Metodo de preparacion de dihidrato de azitromicina cristalino |
| FR2710841B1 (fr) * | 1993-10-05 | 1995-11-17 | Oreal | Composition cosmétique ou pharmaceutique pour la peau, anhydre et stable, à base de rétinol et son utilisation en vue du traitement des maladies de la peau. |
| GB9723669D0 (en) * | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
| NZ528197A (en) * | 2001-04-05 | 2007-04-27 | Collagenex Pharm Inc | Use of a tetracycline compound of treating acne |
| US7211267B2 (en) | 2001-04-05 | 2007-05-01 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
| HRP20010301A2 (en) * | 2001-04-27 | 2001-12-31 | Pliva D D | New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases |
| US9035741B2 (en) * | 2003-06-27 | 2015-05-19 | Stryker Corporation | Foot-operated control console for wirelessly controlling medical devices |
-
2006
- 2006-12-06 US US11/635,127 patent/US7704959B2/en not_active Expired - Fee Related
-
2007
- 2007-09-24 KR KR1020097008632A patent/KR20090064592A/ko not_active Withdrawn
- 2007-09-24 SI SI200730804T patent/SI2086552T1/sl unknown
- 2007-09-24 AU AU2007302663A patent/AU2007302663B2/en not_active Ceased
- 2007-09-24 PT PT07838730T patent/PT2086552E/pt unknown
- 2007-09-24 EP EP07838730A patent/EP2086552B1/en not_active Not-in-force
- 2007-09-24 CN CN2012100346744A patent/CN102614210A/zh active Pending
- 2007-09-24 AT AT07838730T patent/ATE533496T1/de active
- 2007-09-24 RU RU2009116629/15A patent/RU2009116629A/ru unknown
- 2007-09-24 ES ES07838730T patent/ES2377470T3/es active Active
- 2007-09-24 DK DK07838730.5T patent/DK2086552T3/da active
- 2007-09-24 PL PL11188960.6T patent/PL2420240T3/pl unknown
- 2007-09-24 PL PL07838730T patent/PL2086552T3/pl unknown
- 2007-09-24 CN CN2007800406070A patent/CN101534837B/zh not_active Expired - Fee Related
- 2007-09-24 WO PCT/US2007/020583 patent/WO2008042139A2/en not_active Ceased
- 2007-09-24 MX MX2009003484A patent/MX2009003484A/es active IP Right Grant
- 2007-09-24 CA CA002664673A patent/CA2664673A1/en not_active Abandoned
- 2007-09-24 ES ES11188960.6T patent/ES2574677T3/es active Active
- 2007-09-24 EP EP11188960.6A patent/EP2420240B1/en not_active Not-in-force
- 2007-09-24 JP JP2009531388A patent/JP2010505827A/ja active Pending
- 2007-09-24 BR BRPI0719535-4A patent/BRPI0719535A2/pt not_active IP Right Cessation
-
2010
- 2010-04-23 US US12/799,401 patent/US20100216732A1/en not_active Abandoned
-
2012
- 2012-01-17 CY CY20121100054T patent/CY1112650T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2086552A2 (en) | 2009-08-12 |
| CN101534837B (zh) | 2012-04-04 |
| CY1112650T1 (el) | 2016-02-10 |
| EP2420240A1 (en) | 2012-02-22 |
| EP2086552A4 (en) | 2009-11-04 |
| RU2009116629A (ru) | 2010-11-10 |
| WO2008042139A2 (en) | 2008-04-10 |
| HK1130667A1 (en) | 2010-01-08 |
| US7704959B2 (en) | 2010-04-27 |
| BRPI0719535A2 (pt) | 2014-01-14 |
| EP2420240B1 (en) | 2016-05-11 |
| AU2007302663A1 (en) | 2008-04-10 |
| DK2086552T3 (da) | 2012-01-09 |
| PL2420240T3 (pl) | 2016-10-31 |
| US20080081790A1 (en) | 2008-04-03 |
| KR20090064592A (ko) | 2009-06-19 |
| MX2009003484A (es) | 2009-10-26 |
| SI2086552T1 (sl) | 2012-01-31 |
| PL2086552T3 (pl) | 2012-03-30 |
| US20100216732A1 (en) | 2010-08-26 |
| WO2008042139A3 (en) | 2008-10-16 |
| AU2007302663B2 (en) | 2012-07-12 |
| CN102614210A (zh) | 2012-08-01 |
| JP2010505827A (ja) | 2010-02-25 |
| ES2574677T3 (es) | 2016-06-21 |
| PT2086552E (pt) | 2011-12-19 |
| CA2664673A1 (en) | 2008-04-10 |
| EP2086552B1 (en) | 2011-11-16 |
| ATE533496T1 (de) | 2011-12-15 |
| CN101534837A (zh) | 2009-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cunliffe et al. | Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle | |
| US11497750B2 (en) | Methods of treating and/or preventing actinic keratosis | |
| ES2377470T3 (es) | Azitromicina para el tratamiento del acné nodular | |
| MX2010012385A (es) | Regimen de terapia para tratar enfermedades relacionadas al acne. | |
| RU2481832C2 (ru) | Применение адапалена и пероксида бензоила для продолжительного лечения угрей обыкновенных | |
| Braathen | Topical clindamycin versus oral tetracycline and placebo in acne vulgaris | |
| Wahab et al. | Isotretinoin versus weekly pulse dose azithromycin in the treatment of acne-a comparative study | |
| US20050158404A1 (en) | Composition and method for treatment of acne | |
| AU2022204106A1 (en) | Methods of treatment of acne vulgaris using topical dapsone compositions | |
| Tangjaturonrusamee et al. | Comparison of pneumatic broadband light plus adapalene gel 0.3% versus adapalene gel 0.3% monotherapy in the treatment of mild to moderate acne | |
| HK1162921A (en) | Azithromycin for the treatment of nodular acne | |
| Brandt et al. | Erythromycin acistrate-an alternative oral treatment for acne | |
| HK1130667B (en) | Azithromycin for the treatment of nodular acne | |
| Durme | Common Dermatoses | |
| Bushuieva et al. | Combination therapy of acne (acne vulgaris) in patients of different age groups | |
| Thuangtong | Chinmanat Tangjaturonrusamee, MD | |
| TUCKER | New Acne Recommendations Stress Combo Tx | |
| Feldman | Common use of prescription off-label therapy for acne in the pediatric population< 12 years old Sonal Parikh, Wake Forest School of Medicine, Winston-Salem, NC, United States; Scott Davis, Wake Forest School of Medicine, Winston-Salem, NC, United States | |
| Minocin | Triax Pharmaceuticals Announces The Launch of MINOCIN®(minocycline HCl) Professional Acne Care (PAC) | |
| Godovanets | The treatment of periodontal disease in children with diffuse nontoxic goiter |